How Targeted Chemotherapy and Immunotherapy are Changing Cancer Care

What if chemotherapy could target tumors without harming the rest of the body? In this episode of *Rx for Biotech*, host Chris Leidli sits down with Christina Coughlin, MD, PhD, CEO of Avacta Therapeutics, to explore a new approach to cancer treatment using targeted chemotherapy and precision oncology. Avacta is developing a novel platform designed to activate powerful cancer drugs only inside the tumor, potentially reducing side effects like damage to the heart, bone marrow, and other healthy tissues. This approach, known as tumor-targeted drug delivery, could redefine how chemotherapy is used across cancers such as triple-negative breast cancer, soft tissue sarcoma, and salivary gland cancer. Christina shares her journey from early work in CAR-T cell therapy and immuno-oncology to leading Avacta’s innovative pre|CISION peptide drug conjugate platform, including its lead asset AVA6000 (faridoxorubicin) now in clinical trials. In this conversation, we discuss: • How targeted chemotherapy works and why it may be safer than traditional chemo • The role of the immune system and immunotherapy in cancer treatment • Why improving drug delivery is one of the biggest challenges in oncology • Key clinical insights from early trials of AVA6000 • What the future of precision medicine and personalized cancer care could look like As cancer treatment evolves, innovations like Avacta’s platform could help patients receive more effective, less toxic therapies tailored to their biology 📌 Learn more about navigating advanced therapies and personalized care at: [https://www.therapy4me.ai] #CancerTreatment #PrecisionMedicine #Chemotherapy #Immunotherapy #Oncology #Biotech #TargetedTherapy #Avacta #RxForBiotech